South and Central America Embolization Agents Market

Market Introduction

South and Central America region for the estimating the market for the embolization agents consist of countries such as Brazil, Argentina, and rest of South and Central America. The region is expected to experience growth opportunities due to rising incidences of stroke in the countries and rise development in the healthcare systems. The market is also expected to grow due to the rising awareness about the tumors and brain aneurysms in the countries of the region. In Brazil, the ischemic stroke is the common type of neurovascular diseases, accounting 61.8% of total deaths in 2016. This data was published by a study titled as ‘The burden of stroke in Brazil in 2016: an analysis of the Global Burden of Disease study findings’ it also stated that percentage was higher among the people aged 70 years and above. However, the mortality rates due to stroke have been reduced in the country. The development and improvements in the country have led to easy access to education and technology. Also, the advancement in primary health care has focused on prevention of the stroke and other neurological disorder. Breast and cervical cancer are common in Brazil, and large segments of the population, particularly in rural areas, have limited access to health care. There isn't a well-established, systematic screening programmed in existence. Each year, an estimated 49.27 new instances of breast cancer, 18.47 new cases of cervical cancer, 6.89 new cases of endometrial cancer, and 1.19 new cases of ovarian cancer are reported per 100,000 people. In addition, across the country, institutes are working towards the growth of the cancer and neuroscience in Brazil. For instance, The Brazilian Institute of Neuroscience and Neurotechnology (BRAINN) is a São Paulo Research Foundation (FAPESP)-funded institute that inspects the molecular mechanisms underlying epilepsy, stroke, and lesions associated with these diseases. INCA is the Brazilian Ministry of Health's body in charge of developing and coordinating integrated cancer prevention and control strategies. These activities include direct, free hospital care for cancer patients under Brazil's Unified Public Health System (SUS). Thus, the developments in the neurological segments are expected to grow the embolization agents market during the forecast period.

The increasing number of COVID-19 cases in Brazil, Peru, Chile, Ecuador, and Venezuela is likely to have negative impact on the South and Central America embolization agents market. For instance, in Brazil, the number of cases has reached ~18,513,305, with 516,119 deaths, as per the world meter data of June 2021. With the onset of the second wave of COVID-19 pandemic, there has been an increasing number of cases in the South American countries. According to the International Council of Nurses, the number of deaths of health professionals in Brazil are greater than the numbers in other countries, which can be associated with the high transmission of the virus. As Brazil has many populated regions with small houses with 6-7 people per house, the virus has spread rapidly. Currently, the countries in this region are rapidly increasing its clinical programs to fight against the novel coronavirus.

 

In this scenario, Brazil is facing enormous difficulties in the management of cancer, head and neck surgeries, chronic neurological disorders such as brain aneurysms, and headache and neurodegenerative diseases. Due to inadequate monitoring, many patients end up being admitted to emergency departments due to decompensation of their cancer and neurological disease. During the pandemic, patients with cancer and stroke, as well as other neurological conditions, have been arriving late at the hospital, and the treatment procedures of such patients fall outside the therapeutic window for acute intervention. In addition, the country also faced difficulties in obtaining beds in the intensive care unit for management of these disease amid the COVID-19 crisis. These factors are limiting the South and Central America embolization agents market growth.

South and Central America Embolization Agents Strategic Insights

Strategic insights for the South and Central America Embolization Agents provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

South and Central America Embolization Agents Report Scope

South and Central America Embolization Agents Regional Insights

The geographic scope of the South and Central America Embolization Agents refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Market Overview and Dynamics

The embolization agents market in South and Central America is expected to grow from US$ 167.17 million in 2021 to US$ 262.40 million by 2028; it is estimated to grow at a CAGR of 6.7% from 2021 to 2028. Growing incidence of hypertension, obesity, smoking, and alcoholism; Hypertension, smoking, alcoholism, and obesity are associated with the development of brain aneurysms. Thus, increasing prevalence of these diseases is likely to fuel the demand for embolization agents market. Kidney cancer is becoming more common in people of all ages, races, and tumor sizes. Hypertension, being overweight, and smoking are all risk factors for kidney cancer. Obesity is associated with high blood pressure, dyslipidemia, diabetes, or insulin resistance, as well as higher fibrinogen and C-reactive protein levels, all of which increase the risk of cardiovascular diseases (CVD) events. Obesity has been associated with a higher risk of high blood pressure, in addition to CVD. Embolizing agents like the Amplatzer Vascular Plug (AVP) was created for peripheral embolization as a modification of the family of Amplatz septal occluders used in the treatment of congenital heart malformations. Thus, increasing prevalence of hypertension, smoking, alcoholism, and obesity requiring mobility assistance is likely to favor the growth of the South and Central America embolization agents market.

Key Market Segments

Based on product, the market is segmented into coils, beads/particles, plugs, detachable balloons, glue, sponge, liquid embolics, sclerosants, precipitating agents, others. The beads/particles segment held the largest share of the market in 2020. Based on coils the market is divided into detachable coils and pushable coils. The pushable coils segment held the largest share of the market in 2020. Based on beads/particles the market is divided into spherical and non-spherical. The pushable non-spherical segment held the largest share of the market in 2020. Based on application, the market is segmented into neurology, oncology, cardiology, peripheral vascular diseases, and others. In 2020, the oncology segment is likely to hold the largest share of the market. The embolization agents market by end user, is segmented into hospitals, ambulatory surgical centers, cardiac centers, and others. The hospitals segment held the largest share of the market in 2020.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the embolization agents market in South and Central America are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Abbott; Boston Scientific Corporation; Cook Medical LLC; DePuy Synthes; KANEKA CORPORATION; Medtronic; Merit Medical Systems Inc; Stryker Corporation; and Terumo Corporation among others.

Reasons to buy report

• To understand the South and Central America embolization agents market landscape and identify market segments that are most likely to guarantee a strong return
• Stay ahead of the race by comprehending the ever-changing competitive landscape for South and Central America embolization agents market
• Efficiently plan M&A and partnership deals in South and Central America embolization agents market by identifying market segments with the most promising probable sales
• Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form South and Central America embolization agents market
• Obtain market revenue forecast for market by various segments from 2021-2028 in South and Central America region.

SOUTH AND CENTRAL AMERICA EMBOLIZATION AGENTS MARKET SEGMENTATION

By Product

• Coils
  • Detachable Coils
  • Pushable Coils
• Beads/ Particles
  • Spherical
  • Non-Spherical
• Plugs
• Detachable Balloons
• Glue
• Sponge
• Liquid Embolics
• Sclerosants
• Precipitating Agents
• Others

By

Application

• Oncology
• Neurology
• Urology
• Cardiology
• Peripheral Vascular Diseases
• Others

By

End User

• Hospitals
• Cardiac Centers
• Ambulatory Surgical Centers
• Others  

By Country

• Brazil
• Argentina
• Rest of South and Central America

Company Profiles

• Abbott
• Boston Scientific Corporation
• Cook Medical LLC
• DePuy Synthes
• KANEKA CORPORATION
• Medtronic
• Merit Medical Systems Inc
• Stryker Corporation
• Terumo Corporation